ESTRO 2025 - Abstract Book

S1422

Clinical - Lung

ESTRO 2025

The median age was 64 years, and 58% of the patients were male. The median follow-up duration was 24 months (ranging from 5 to 119 months). The median OS and median DFS were 46 and 14 months, respectively. Radiotherapy was prescribed during the first two cycles of chemotherapy in approximately 66% of the patients, with median OS was 52 months in those patients. Immunotherapy was added to the first-line treatment in 30% of the patients. Prophylactic cranial irradiation was administered to 25 patients (42%). Grade 3 acute esophagitis was documented in 8.5% of patients. Grade 3 radiation pneumonitis was noted in 2 patients (3.4%). One patient had Grade 5 toxicity due to immunotherapy. Overall, recurrence was observed in 35 patients. Seventy percent of the recurrences were identified as distant. Isolated local recurrence was detected in only 5 patients. Both local and distant recurrences were observed in five patients. Conclusion: Dose escalation was effective and safe in our cohort for local disease control; however, since the majority of our patients experienced distant failure, impact of loco-regional control sound to be lost in survival outcomes with a median OS of 46 months in comparison to 62.4 months by Yu et al. The limitations of our study need to be considered in comparison such as retrospective nature of our cohort treated in a decade, unpredictable selection biases, and the initiation of radiotherapy with the third or fourth chemotherapy cycle in 30%. References: 1) Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D, Zhuo M, Chen H, Huang W, Zhu Z, Zhang M, Song Y, Li Q, Ma Z, Wang Q, Qu Y, Yu R, Yu H, Zhao J, Shi A; Trial Management Group. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024 Oct;12(10):799-809. doi: 10.1016/S2213 2600(24)00189-9. Epub 2024 Aug 12. Erratum in: Lancet Respir Med. 2024 Oct 18:S2213-2600(24)00343-6. doi: 10.1016/S2213-2600(24)00343-6. PMID: 39146944. Keywords: BID, High Dose Radiation, Survival Outcome Digital Poster Survival and Toxicity Outcomes Following Radiotherapy in Patients with Lung Cancer and Co-existing Interstitial Lung Disease. Sarah Bowen Jones 1 , Gerard Gurumurthy 1 , Ahmad Lodhi 2 , Aqeel Umar 3 , Xin Wang 4 , Conal Hayton 5 , Danya Abdulwahid 1 , Claire Barker 1 , Kathryn Banfill 1 , Neil Bayman 1 , Clara Chan 1 , Joanna Coote 1 , Margaret Harris 1 , Jennifer King 1 , Laura Pemberton 1 , Hamid Sheikh 1 , David Woolf 1 , Ahmed Salem 6 , Corinne Faivre-Finn 1 1 Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 2 Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 3 Radiology, Manchester University Foundation Trust, Manchester, United Kingdom. 4 Clinical outcome and data unit, The Christie NHS Foundation Trust, Manchester, United Kingdom. 5 Respiratory medicine, Manchester University Foundation Trust, Manchester, United Kingdom. 6 Faculty of Medicine, The Hashemite University, Zarqa, Jordan Purpose/Objective: Patients with interstitial lung disease (ILD) have an increased risk of lung cancer compared to the general population. Previous limited evidence has reported poor survival outcomes and high levels of toxicity following radiotherapy in these patients. Interstitial lung abnormalities (ILA) are pre-clinical radiological features, which may progress to clinical ILD. This retrospective analysis evaluates outcomes and treatment-related toxicity in patients with ILD or ILA. 4029